nevirapine has been researched along with Viremia in 24 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Viremia: The presence of viruses in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Switching subjects with persistently undetectable HIV-1 viremia under antiretroviral treatment (ART) to once-daily tenofovir/emtricitabine (or lamivudine) + nevirapine is a cost-effective and well-tolerated strategy." | 7.81 | Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia. ( Bravo, I; Clotet, B; Llibre, JM; Martin-Iguacel, R; Ornelas, A; Paredes, R; Puig, J; Santos, JR, 2015) |
| "To determine whether residual plasma viremia in HIV(+) patients on nevirapine-including antiretroviral therapy (ART) is related to anti-HIV cellular immune responses, a case-control study was conducted comparing residual viremia in patients with detectable and undetectable Gag-specific T-cell responses." | 7.80 | Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response. ( Allavena, C; Billaud, E; Ferré, V; McIlroy, D; Raffi, F; Rodallec, A, 2014) |
| "Among HIV-infected children previously exposed to nevirapine, switching to nevirapine-based therapy after achieving viral suppression with a ritonavir-boosted lopinavir regimen resulted in lower rates of viremia greater than 50 copies/mL than maintaining the primary ritonavir-boosted lopinavir regimen." | 5.14 | Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. ( Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Sherman, G; Stehlau, R; Tsai, WY, 2010) |
| "All HIV-infected patients receiving a stable PI/r-based antiretroviral regimen, with persistently suppressed viremia, naïve to non-nucleoside analogues and to integrase strand transfer inhibitors, with mixed hyperlipidaemia, and who underwent a switch from PI/r to nevirapine (Group A) or raltegravir (Group B) or who started rosuvastatin at 10 mg daily (group C) with unchanged antiretroviral regimen were enrolled into the study." | 3.85 | Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). ( Bon, I; Borderi, M; Bussini, L; Calza, L; Colangeli, V; Magistrelli, E; Re, MC; Viale, P, 2017) |
| " We assessed the relationship between plasma lopinavir or nevirapine concentrations and the risk of subsequent viremia in children initially suppressed on antiretroviral therapy." | 3.83 | Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. ( Abrams, EJ; Castel, S; Coovadia, A; Kuhn, L; Maartens, G; McIlleron, H; Moholisa, RR; Patel, F; Pinillos, F; Schomaker, M; Strehlau, R; Wiesner, L, 2016) |
| "To determine whether residual plasma viremia in HIV(+) patients on nevirapine-including antiretroviral therapy (ART) is related to anti-HIV cellular immune responses, a case-control study was conducted comparing residual viremia in patients with detectable and undetectable Gag-specific T-cell responses." | 3.80 | Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response. ( Allavena, C; Billaud, E; Ferré, V; McIlroy, D; Raffi, F; Rodallec, A, 2014) |
| "To compare the level of HIV-1 residual viremia, defined by a viral load below 50 copies/ml in patients receiving a tenofovir/emtricitabine and nevirapine (NVP) or efavirenz (EFV)-containing regimen." | 3.77 | Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. ( Calvez, V; Flandre, P; Fourati, S; Girard, PM; Haïm-Boukobza, S; Katlama, C; Lavignon, M; Marcelin, AG; Morand-Joubert, L; Sayon, S; Simon, A; Valin, N, 2011) |
| "Nevirapine resistance after failed prophylaxis to prevent mother-to-child human immunodeficiency virus (HIV) transmission can compromise subsequent nevirapine-based highly active antiretroviral therapy (HAART)." | 3.77 | Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. ( Abrams, EJ; Chen, YH; Coovadia, A; Kuhn, L; Meyers, T; Moorthy, A; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY, 2011) |
| "To describe the experience of four London HIV centres prescribing nevirapine (NVP) to HIV-1 infected pregnant women with respect to immunological and virological response, tolerability and pregnancy outcome." | 3.71 | Experience of nevirapine use in a London cohort of HIV-infected pregnant women. ( de Ruiter, A; Easterbrook, P; Edwards, SG; Hay, P; Larbalestier, N; Taylor, GP; Welch, J, 2001) |
| "Disease progression was particularly rapid, 85% infants meeting WHO criteria for ART within 6 months." | 2.73 | High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. ( Blanckenberg, N; Goulder, P; Kiepiela, P; McCarthy, N; Mkhwanazi, N; Mphatswe, W; Prendergast, A; Thobakgale, C; Tudor-Williams, G; Walker, BD, 2007) |
| " Overall, in 12 patients treated with hydroxyurea, 33 adverse events were reported versus 19 reported for 12 patients who did not receive hydroxyurea (p <." | 2.70 | Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. ( Cahn, P; Federico, A; Kijak, G; Montaner, JS; Ochoa, C; Perez, H; Salomon, H; Zala, C, 2002) |
| "Nevirapine was rapidly absorbed, but the time to peak plasma concentrations increased with higher doses." | 2.68 | Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. ( Bryson, Y; Cort, S; Lamson, M; Luzuriaga, K; McSherry, G; Robinson, J; Scott, G; Stechenberg, B; Sullivan, JL, 1996) |
| "Nevirapine was added to the drug regiment of eight children with HIV infection treated with the combination of zidovudine and didanosine who had increasing levels of serum p24 antigen." | 1.29 | Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus. ( Anderson, B; Farley, M; Fox, C; Luzuriaga, K; Mueller, BU; Pizzo, PA; Schwartzentruber, DJ; Sei, S; Sullivan, JL; Tudor-Williams, G; Venzon, DJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (20.83) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattacharya, D | 1 |
| Guo, R | 1 |
| Tseng, CH | 1 |
| Emel, L | 1 |
| Sun, R | 1 |
| Chiu, SH | 1 |
| Stranix-Chibanda, L | 1 |
| Chipato, T | 1 |
| Mohtashemi, NZ | 1 |
| Kintu, K | 1 |
| Manji, KP | 1 |
| Moodley, D | 1 |
| Thio, CL | 1 |
| Maldonado, Y | 1 |
| Currier, JS | 1 |
| Calza, L | 1 |
| Magistrelli, E | 1 |
| Colangeli, V | 1 |
| Borderi, M | 1 |
| Bussini, L | 1 |
| Bon, I | 1 |
| Re, MC | 1 |
| Viale, P | 1 |
| Allavena, C | 2 |
| Rodallec, A | 2 |
| Sécher, S | 1 |
| Reliquet, V | 1 |
| Baffoin, S | 1 |
| André-Garnier, E | 1 |
| Billaud, E | 2 |
| Raffi, F | 2 |
| Ferré, V | 2 |
| McIlroy, D | 1 |
| Gupta, RK | 1 |
| Goodall, RL | 1 |
| Ranopa, M | 1 |
| Kityo, C | 1 |
| Munderi, P | 1 |
| Lyagoba, F | 1 |
| Mugarura, L | 1 |
| Gilks, CF | 1 |
| Kaleebu, P | 1 |
| Pillay, D | 1 |
| Ngemu, EK | 1 |
| Khayeka-Wandabwa, C | 1 |
| Kweka, EJ | 1 |
| Choge, JK | 1 |
| Anino, E | 1 |
| Oyoo-Okoth, E | 1 |
| Shearer, K | 1 |
| Brennan, AT | 1 |
| Maskew, M | 1 |
| Long, L | 1 |
| Berhanu, R | 1 |
| Sanne, I | 1 |
| Fox, MP | 1 |
| Llibre, JM | 1 |
| Bravo, I | 1 |
| Ornelas, A | 1 |
| Santos, JR | 1 |
| Puig, J | 1 |
| Martin-Iguacel, R | 1 |
| Paredes, R | 1 |
| Clotet, B | 1 |
| Moholisa, RR | 1 |
| Schomaker, M | 1 |
| Kuhn, L | 3 |
| Castel, S | 1 |
| Wiesner, L | 1 |
| Coovadia, A | 3 |
| Strehlau, R | 2 |
| Patel, F | 1 |
| Pinillos, F | 1 |
| Abrams, EJ | 3 |
| Maartens, G | 1 |
| McIlleron, H | 1 |
| Stehlau, R | 1 |
| Meyers, T | 2 |
| Martens, L | 1 |
| Sherman, G | 2 |
| Hunt, G | 1 |
| Hu, CC | 1 |
| Tsai, WY | 2 |
| Morris, L | 1 |
| Haïm-Boukobza, S | 1 |
| Morand-Joubert, L | 1 |
| Flandre, P | 1 |
| Valin, N | 1 |
| Fourati, S | 1 |
| Sayon, S | 1 |
| Lavignon, M | 1 |
| Simon, A | 1 |
| Girard, PM | 1 |
| Katlama, C | 1 |
| Calvez, V | 2 |
| Marcelin, AG | 2 |
| Moorthy, A | 1 |
| Chen, YH | 1 |
| Persaud, D | 1 |
| Weissbrich, B | 1 |
| Langmann, P | 1 |
| Schubert, J | 1 |
| Jassoy, C | 1 |
| Klinker, H | 1 |
| Gianotti, N | 1 |
| Boeri, E | 1 |
| Maillard, M | 1 |
| Serra, G | 1 |
| Ratti, D | 1 |
| Gallotta, G | 1 |
| Vacchini, D | 1 |
| Tremolada, Y | 1 |
| Castagna, A | 1 |
| Martinez, V | 1 |
| Morini, JP | 1 |
| Deleuze, J | 1 |
| Krivine, A | 1 |
| Gorin, I | 1 |
| Yerly, S | 1 |
| Perrin, L | 1 |
| Peytavin, G | 1 |
| Dupin, N | 1 |
| Jakobsen, MR | 1 |
| Tolstrup, M | 1 |
| Bertelsen, L | 1 |
| Laursen, A | 1 |
| Obel, N | 1 |
| Ostergaard, L | 1 |
| Mohey, R | 1 |
| Mphatswe, W | 1 |
| Blanckenberg, N | 1 |
| Tudor-Williams, G | 2 |
| Prendergast, A | 1 |
| Thobakgale, C | 1 |
| Mkhwanazi, N | 1 |
| McCarthy, N | 1 |
| Walker, BD | 1 |
| Kiepiela, P | 1 |
| Goulder, P | 1 |
| Cohen, J | 1 |
| Mueller, BU | 1 |
| Sei, S | 1 |
| Anderson, B | 1 |
| Luzuriaga, K | 2 |
| Farley, M | 1 |
| Venzon, DJ | 1 |
| Schwartzentruber, DJ | 1 |
| Fox, C | 1 |
| Sullivan, JL | 2 |
| Pizzo, PA | 1 |
| Bryson, Y | 1 |
| McSherry, G | 1 |
| Robinson, J | 1 |
| Stechenberg, B | 1 |
| Scott, G | 1 |
| Lamson, M | 1 |
| Cort, S | 1 |
| de Jong, MD | 1 |
| de Boer, RJ | 1 |
| de Wolf, F | 1 |
| Foudraine, NA | 1 |
| Boucher, CA | 1 |
| Goudsmit, J | 1 |
| Lange, JM | 1 |
| James, JS | 1 |
| Edwards, SG | 1 |
| Larbalestier, N | 1 |
| Hay, P | 1 |
| de Ruiter, A | 1 |
| Welch, J | 1 |
| Taylor, GP | 1 |
| Easterbrook, P | 1 |
| Zala, C | 1 |
| Salomon, H | 1 |
| Ochoa, C | 1 |
| Kijak, G | 1 |
| Federico, A | 1 |
| Perez, H | 1 |
| Montaner, JS | 1 |
| Cahn, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412] | Phase 3 | 2,026 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Clinical Relevance of Nevirapine Resistance[NCT00117728] | Phase 3 | 250 participants (Anticipated) | Interventional | 2005-04-30 | Recruiting | ||
| A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Pharmacokinetics, Safety, Tolerance, and Activity of Nevirapine (BI-RG-587) Alone and in Combination With AZT in Mildly to Moderately Symptomatic HIV-1 Infected Children[NCT00001111] | 35 participants | Interventional | Completed | ||||
| A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children[NCT00000634] | 6 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months
| Intervention | Number of Adverse Events (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-Threatening | Severe | Moderate | Mild | |
| Nevirapine | 26 | 87 | 375 | 694 | 832 |
| Placebo | 30 | 87 | 332 | 677 | 838 |
(NCT00074412)
Timeframe: At Month 6
| Intervention | participants (Number) | |
|---|---|---|
| # of HIV infections at 6 months | # of Infants at risk for HIV infection at 6 months | |
| Nevirapine | 8 | 700 |
| Placebo | 18 | 699 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # Infant Deaths at 18 months | # Infants at risk of death at 18 months | |
| Nevirapine | 26 | 678 |
| Placebo | 30 | 684 |
(NCT00074412)
Timeframe: At Months 6 and 18
| Intervention | participants (Number) | |
|---|---|---|
| Number of Infants Alive and HIV-free at 6 months | Number of Infants Alive and HIV-free at 18 months | |
| Nevirapine | 689 | 629 |
| Placebo | 683 | 616 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # of infants with HIV infection at 18 months | # of infants @ risk for HIV infection at 18 months | |
| Nevirapine | 16 | 664 |
| Placebo | 23 | 663 |
7 trials available for nevirapine and Viremia
| Article | Year |
|---|---|
Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
Topics: Anti-HIV Agents; Birth Weight; Coinfection; Double-Blind Method; Female; Hepatitis B; Hepatitis B vi | 2021 |
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Nevirapine; Viral Load; | 2014 |
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 | 2014 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; | 2010 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; | 2010 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; | 2010 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; | 2010 |
High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Thera | 2007 |
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy | 1996 |
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy | 1996 |
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy | 1996 |
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy | 1996 |
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Inf | 2002 |
17 other studies available for nevirapine and Viremia
| Article | Year |
|---|---|
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
Topics: Adult; Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cholesterol | 2017 |
Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropane | 2013 |
Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; En | 2014 |
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; | 2014 |
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; HIV-1; Humans; Lamivudine; | 2015 |
Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.
Topics: Child, Preschool; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavi | 2016 |
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; | 2011 |
Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.
Topics: Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Resistance, Viral; Female; Genotype; H | 2011 |
Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups.
Topics: Acute Disease; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis C, Chronic; | 2003 |
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; | 2004 |
HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HI | 2005 |
Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Drug Ther | 2007 |
High turnover of HIV in blood revealed by new studies.
Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; HIV; HIV Infections; HIV Proteas | 1995 |
Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.
Topics: Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; DNA, Viral; Dru | 1996 |
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Indinavi | 1997 |
New information on HIV rapid turnover--what does it mean?
Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indina | 1995 |
Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV-1; Humans; | 2001 |